Eli Lilly has agreed to buy a gene-editing programme for cardiovascular diseases from Beam Therapeutics in a deal, valued at up to $600 million, that ties in with the biotech’s recent restructuring drive.Beam is selling Lilly the opt-in rights to a trio of candidates covered by an agreement it signed with Verve Therapeutics in 2019 […]